Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma

Inclusion Criteria:

Each patient must meet all of the following inclusion criteria for study enrollment:

* Age ≥18 with ability to provide written informed consent
* Pathologically confirmed WHO Grade IV Gliobastoma prior receiving radiotherapy
* Prior radiotherapy to a dose of ≥50Gy
* No signs of distant metastases
* Baseline laboratory assessment including CBC and blood chemistry, ANC \> or equal 1500, Platelet count greater or equal 100. Liver function tests and creatinine not greater than twice ULN.
* Patient should not be pregnant. Urine or blood β-HCG within 14 days prior to study start for females who are not atleast one year post-menopausal or who have ot undergone a surgical sterilization procedure
* A baseline MRI scan of the brain is required to determine how much tumor is present for properly planning patient's radiotherapy.
* Karnofsky Performance Status (KPS) below 60 or ECOG of 3 or 4
* Any number or type of prior chemotherapy is allowed (patient may receive concurrent or adjuvant systemic therapy such as cetuximab at the discretion of the treating oncologic team).

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not eligible for enrollment:

* Evidence of distant metastases on any staging or imaging modality
* Women who are breast feeding, or have a positive pregnancy test (reproductive age should use effective birth control during study)
* Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the principal investigator.
* Karnofsky Performance Status less than 50
* Prior radiotherapy to involved site in brain.